Study guide

11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

Key Takeaways Explain This Topic AI

The KDIGO consensus criteria stage Acute Kidney Injury (AKI) by serum creatinine elevation (Stage 1: >= 0.3 mg/dL within 48h or 1.5–1.9x baseline within 7d; Stage 2: 2.0–2.9x; Stage 3: >= 3.0x baseline, creatinine >= 4.0 mg/dL, or RRT initiation) and urine output (< 0.5 mL/kg/h for >= 6h).

Contrast-associated AKI (CA-AKI) is mitigated primarily by intravascular volume expansion with isotonic crystalloids (0.9% NaCl or balanced fluids at 1–1.5 mL/kg/h); prophylactic N-acetylcysteine (NAC) and sodium bicarbonate show no consistent clinical benefit over isotonic fluids in randomized trials (e.g., PRESERVE).

Extracorporeal drug clearance during renal replacement therapy depends on molecular weight (IHD cutoff ~500 Da vs high-flux/CRRT cutoff up to 20,000–30,000 Da), protein binding (only unbound free drug is filtered; drugs with > 80–90% binding are non-dialyzable), volume of distribution (Vd < 0.7 L/kg is dialyzable, whereas Vd > 1–2 L/kg is tissue-sequestered), and water solubility.

In septic shock requiring continuous renal replacement therapy (CRRT), standard effluent rates (20–25 mL/kg/h) aggressively clear hydrophilic antimicrobials (vancomycin, cefepime, meropenem); clinicians must administer full, unadjusted loading doses regardless of renal function, followed by maintenance regimens adjusted to the CRRT effluent rate to avoid subtherapeutic failure.

Emergency department nephrotoxic stewardship requires avoiding the 'triple whammy' combination (ACEI/ARB + Diuretic + NSAID), utilizing single-daily extended-interval aminoglycoside dosing, and guiding vancomycin therapy by 24-hour AUC/MIC (400–600 mg*h/L) rather than elevated trough targets.

Last updated: October 2026

11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around clinical emergency medicine pharmacotherapy principles and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.

KDIGO Staging & Diagnosis of Acute Kidney Injury

Acute Kidney Injury (AKI) represents an abrupt decline in glomerular filtration rate (GFR) resulting in the accumulation of nitrogenous waste products (urea, creatinine) and loss of fluid and electrolyte homeostasis. The Kidney Disease: Improving Global Outcomes (KDIGO) consensus criteria standardize AKI definition and staging based on serum creatinine changes and oliguria duration:

KDIGO Stage Serum Creatinine Criteria Urine Output (UOP) Criteria

Stage 1 Increase in SCr ≥ 0.3 mg/dL \text{SCr} \ge 0.3\text{ mg/dL} SCr ≥ 0.3 mg/dL within 48 hours, OR increase ≥ 1.5 to 1.9 × \ge 1.5\text{ to }1.9\times ≥ 1.5 to 1.9 × baseline within 7 days < 0.5 mL/kg/h < 0.5\text{ mL/kg/h} < 0.5 mL/kg/h for 6 to 12 consecutive hours

Stage 2 Increase in SCr 2.0 to 2.9 × \text{SCr } 2.0\text{ to }2.9\times SCr 2.0 to 2.9 × baseline < 0.5 mL/kg/h < 0.5\text{ mL/kg/h} < 0.5 mL/kg/h for ≥ 12 \ge 12 ≥ 12 consecutive hours

Stage 3 Increase in SCr ≥ 3.0 × \text{SCr } \ge 3.0\times SCr ≥ 3.0 × baseline, OR SCr ≥ 4.0 mg/dL \text{SCr} \ge 4.0\text{ mg/dL} SCr ≥ 4.0 mg/dL with acute rise ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL , OR initiation of Renal Replacement Therapy (RRT) < 0.3 mL/kg/h < 0.3\text{ mL/kg/h} < 0.3 mL/kg/h for ≥ 24 \ge 24 ≥ 24 hours, OR anuria for ≥ 12 \ge 12 ≥ 12 consecutive hours

Clinical Limitations of Serum Creatinine in Emergency Care

Serum creatinine is a delayed surrogate marker of renal function. Following an acute ischemic or nephrotoxic insult, serum creatinine accumulation lags 24 to 48 hours behind the true drop in GFR. Furthermore, serum creatinine is confounded by muscle mass, age, baseline protein intake, and intravascular volume overload (where aggressive crystalloid resuscitation hemodilutes creatinine, masking significant AKI).

Contrast-Associated AKI (CA-AKI) Prevention

Contrast-Associated Acute Kidney Injury (CA-AKI)—historically termed contrast-induced nephropathy (CIN)—is defined as an absolute increase in serum creatinine ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL or a relative increase ≥ 50 % \ge 50\% ≥ 50% over baseline occurring within 48 to 72 hours following intravascular administration of iodinated radiocontrast media.

Pathophysiological Mechanisms

Renal Medullary Hypoxia : Radiocontrast media triggers intense, prolonged vasoconstriction of the renal descending vasa recta, mediated by endothelin, adenosine, and reactive oxygen species, collapsing oxygen delivery to the metabolically active medullary thick ascending limb of Henle.

Direct Tubular Cytotoxicity : Filtered hyperosmolar contrast is concentrated in tubular fluid, directly damaging proximal tubular epithelial cells via oxidative stress, mitochondrial fragmentation, and apoptosis. CA-AKI PREVENTION: EVIDENCE VS MYTHS

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ PROVEN EFFECTIVE: INTRAVENOUS VOLUME EXPANSION │
  • │ • Isotonic Crystalloids (0.9% NaCl or Balanced Crystalloid) │
  • │ • Regimen: 1.0–1.5 mL/kg/h for 3–12h pre- and 6–12h post-contrast │
  • │ • Urgent ED Regimen: 3 mL/kg IV over 1 hour pre-contrast │
  • │ • Mechanism: Expands intravascular volume, suppresses renin-angiotensin- │
  • │ aldosterone axis, dilutes contrast in tubular lumen, accelerates flow │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ INEFFECTIVE / NOT RECOMMENDED (PRESERVE TRIAL 2018): │
  • │ • N-Acetylcysteine (NAC): No benefit over isotonic saline │
  • │ • Sodium Bicarbonate Infusion: No superiority over isotonic saline │
  • │ • Prophylactic Hemodialysis: Fails to prevent CA-AKI; may worsen outcomes │
  • └─────────────────────────────────────────────────────────────────────────────┘

Important

The landmark PRESERVE trial (NEJM 2018, n=5,177) definitively proved that among patients with pre-existing chronic kidney disease undergoing angiography, neither intravenous sodium bicarbonate nor oral N-acetylcysteine showed any reduction in contrast-associated AKI, need for dialysis, or 90-day all-cause mortality compared with intravenous 0.9% normal saline. Isotonic crystalloid volume expansion remains the sole proven prophylactic intervention.

Physicochemical Determinants of Extracorporeal Drug Dialyzability

When evaluating whether a drug is cleared by intermittent hemodialysis (IHD) or continuous renal replacement therapy (CRRT: CVVH, CVVHD, CVVHDF), emergency medicine specialists must assess four fundamental physicochemical and pharmacokinetic properties: DETERMINANTS OF DRUG DIALYZABILITY

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. MOLECULAR WEIGHT (MW) │
  • │ • Low-flux IHD filter cutoff: ~500–1,000 Daltons │
  • │ • High-flux IHD & CRRT membrane pore cutoff: ~20,000–30,000 Daltons │
  • │ • Small molecules (<500 Da) easily cleared; large molecules trapped │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 2. PROTEIN BINDING (UNBOUND FRACTION, fu) │
  • │ • Only the free, unbound drug fraction passes through membrane pores │
  • │ • Drugs with >80%–90% protein binding (e.g., ceftriaxone) NOT dialyzable │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 3. VOLUME OF DISTRIBUTION (Vd) │
  • │ • Low Vd (<0.7 L/kg): Drug confined to plasma water ──> High Dialyzability│
  • │ • High Vd (>1–2 L/kg): Drug sequestered in deep tissues ──> NOT Dialyzable│
  • │ (Post-dialysis plasma concentration rebound occurs) │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 4. WATER SOLUBILITY VS LIPOPHILICITY │
  • │ • Hydrophilic drugs partition into dialysate/filtrate water │
  • │ • Lipophilic drugs distribute into cellular membranes and adipose tissue │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Dialysis Clearance Matrix for High-Yield Emergency Medications

Medication Molecular Weight Protein Binding Volume of Distribution (Vd) Low-Flux IHD Clearance CRRT Clearance Clinical Dosing Strategy

Gentamicin / Tobramycin 467 Da 467\text{ Da} 467 Da < 10 % <10\% < 10% 0.25 to 0.3 L/kg 0.25\text{ to }0.3\text{ L/kg} 0.25 to 0.3 L/kg High ( > 50 % >50\% > 50% ) High Administer full loading dose ( 2.5 mg/kg 2.5\text{ mg/kg} 2.5 mg/kg ); in IHD, redose post-dialysis; in CRRT, dose by effluent flow rate.

Cefepime 480 Da 480\text{ Da} 480 Da 20 % 20\% 20% 0.25 to 0.3 L/kg 0.25\text{ to }0.3\text{ L/kg} 0.25 to 0.3 L/kg High ( > 60 % >60\% > 60% ) High Full 2 g 2\text{ g} 2 g load; IHD: 1 g 1\text{ g} 1 g post-HD; CRRT: 2 g 2\text{ g} 2 g IV q12h (or 1 g 1\text{ g} 1 g q8h) to avoid neurotoxicity or subtherapeutic failure.

Meropenem 383 Da 383\text{ Da} 383 Da 2 % 2\% 2% 0.35 L/kg 0.35\text{ L/kg} 0.35 L/kg High ( > 50 % >50\% > 50% ) High Full 1 to 2 g 1\text{ to }2\text{ g} 1 to 2 g load; CRRT: 1 g 1\text{ g} 1 g IV q8h (extended 3h infusion) during high-effluent sepsis resuscitation.

Vancomycin 1 , 449 Da 1,449\text{ Da} 1 , 449 Da 50 % to 55 % 50\%\text{ to }55\% 50% to 55% 0.4 to 0.7 L/kg 0.4\text{ to }0.7\text{ L/kg} 0.4 to 0.7 L/kg Negligible in Low-Flux; Moderate in High-Flux Substantial Full weight-based load ( 25 to 30 mg/kg 25\text{ to }30\text{ mg/kg} 25 to 30 mg/kg ); in CRRT, maintain 15 to 20 mg/kg 15\text{ to }20\text{ mg/kg} 15 to 20 mg/kg q12–24h to target AUC 400–600.

Ceftriaxone 554 Da 554\text{ Da} 554 Da 90 % to 95 % 90\%\text{ to }95\% 90% to 95% 0.15 L/kg 0.15\text{ L/kg} 0.15 L/kg Negligible ( < 5 % <5\% < 5% ) Negligible No supplemental dosing required post-IHD or during CRRT due to extreme protein binding.

Digoxin 781 Da 781\text{ Da} 781 Da 25 % 25\% 25% 6.0 to 7.0 L/kg 6.0\text{ to }7.0\text{ L/kg} 6.0 to 7.0 L/kg Negligible ( < 3 % <3\% < 3% ) Negligible Non-dialyzable due to massive tissue sequestration; post-dialysis rebound occurs. Treat toxicity with Fab fragments.

CRRT vs IHD Drug Dosing Principles in Sepsis

Continuous Renal Replacement Therapy (CRRT)—administered as Continuous Veno-Venous Hemofiltration (CVVH, convective), Continuous Veno-Venous Hemodialysis (CVVHD, diffusive), or Continuous Veno-Venous Hemodiafiltration (CVVHDF, combined)—is preferred in hemodynamically unstable critically ill patients because continuous fluid and solute removal avoids the precipitous hypotension seen with intermittent hemodialysis.

The "Septic Shock Under-Dosing" Crisis in CRRT

In critically ill septic shock patients undergoing CRRT, two concurrent physiological forces dramatically alter drug kinetics:

Massively Expanded Volume of Distribution : Capillary endothelial leak and aggressive crystalloid volume resuscitation expand the extracellular fluid space, diluting hydrophilic antibiotics (beta-lactams, aminoglycosides, glycopeptides).

High Continuous Extracorporeal Clearance : Recommended CRRT effluent flow rates of 20 to 25 mL/kg/h clear hydrophilic drugs at roughly the rate of a native GFR of 25 to 35 mL/min (a 25 mL/kg/h effluent in a 70 kg adult is about 29 mL/min).

Caution

Dosing septic shock patients on CRRT using historical "anuric renal failure" guidelines (e.g., administering cefepime 1 g every 48 hours or meropenem 500 mg every 24 hours) guarantees subtherapeutic antimicrobial exposure and directly increases mortality from uncontrolled bacteremia and septic shock.

Golden Rules of RRT Resuscitation Antimicrobial Dosing

Rule 1: Always Administer a Full, Unadjusted Loading Dose :

Initial drug distribution depends strictly on the volume of distribution ( V d V_d V d ​ ), NOT on renal clearance or dialysis modality.

Administer full weight-based loading doses immediately in the ED: Vancomycin 25 to 30 mg/kg , Cefepime 2 g IV , Meropenem 2 g IV , Piperacillin-Tazobactam 4.5 g IV .

Rule 2: Dose CRRT Maintenance by Effluent Rate :

At standard effluent flow rates ( 20 to 25 mL/kg/h 20\text{ to }25\text{ mL/kg/h} 20 to 25 mL/kg/h ), maintenance dosing should approximate moderate renal impairment (GFR roughly 25–50 mL/min). For example, use Cefepime 2 g IV every 12 hours (or 1 g IV every 8 hours) or Meropenem 1 g IV every 8 hours via extended infusions (over 3 hours) to optimize time-dependent pharmacodynamics ( f T > MIC fT > \text{MIC} f T > MIC ). Adjust down only if effluent flow is interrupted or reduced.

Emergency Department Nephrotoxic Stewardship

Medication stewardship in the emergency department focuses on early identification of drug-induced nephrotoxic combinations, individualized dosing adjustments, and proactive laboratory monitoring.

The "Triple Whammy" Renal Collapse

The concurrent administration of an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) + Loop Diuretic + Nonsteroidal Anti-inflammatory Drug (NSAID) creates a hemodynamic collapse of intraglomerular filtration pressure. THE "TRIPLE WHAMMY" HEMODYNAMIC COLLAPSE

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. LOOP DIURETIC (Furosemide): │
  • │ --> Promotes systemic intravascular volume depletion │
  • │ --> Reduces renal plasma inflow and baseline perfusion │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 2. NSAID (Ketorolac / Ibuprofen): │
  • │ --> Blocks COX-1 and COX-2 synthesis of prostaglandins (PGE2, PGI2) │
  • │ --> Constricts the AFFERENT arteriole (impedes glomerular blood inflow) │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 3. ACE INHIBITOR / ARB (Lisinopril / Losartan): │
  • │ --> Inhibits Angiotensin II-mediated vasoconstriction │
  • │ --> Dilates the EFFERENT arteriole (allows unrestricted blood outflow) │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ RESULT: Glomerular capillary hydrostatic pressure plummets ──> Acute AKI │
  • └─────────────────────────────────────────────────────────────────────────────┘

Clinical Action in ED : Avoid prescribing parenteral or oral NSAIDs (such as ketorolac) in elderly patients or those taking baseline ACEI/ARBs and diuretics. Utilize multimodal non-nephrotoxic analgesics (acetaminophen, topical lidocaine, regional nerve blocks, or low-dose opioids).

Single-Daily Extended-Interval Aminoglycoside Dosing

Aminoglycosides (gentamicin, tobramycin, amikacin) exhibit concentration-dependent bacterial killing (optimal C max ⁡ / MIC ≥ 8 to 10 C_{\max}/\text{MIC} \ge 8\text{ to }10 C m a x ​ / MIC ≥ 8 to 10 ) coupled with saturable receptor-mediated endocytosis into renal proximal tubular cells via the megalin/cubilin receptor complex.

Pharmacokinetic Rationale : Administering a large single daily dose ( 5 to 7 mg/kg of gentamicin/tobramycin) saturates proximal tubular uptake while producing high peak concentrations. As serum concentrations decline over the 24-hour dosing interval to undetectable levels ( < 0.5 to 1.0 mcg/mL < 0.5\text{ to }1.0\text{ mcg/mL} < 0.5 to 1.0 mcg/mL ), intracellular aminoglycosides are slowly cleared out of tubular lysosomes back into urine, minimizing cortical drug accumulation and dramatically reducing nephrotoxicity compared to traditional multiple daily dosing (1.5 to 2 mg/kg q8h).

Vancomycin AUC24/MIC Stewardship vs Trough Targets

The updated 2020 consensus guidelines by ASHP/IDSA/PIDS/SIDP recommend against targeting elevated vancomycin trough concentrations of 15 to 20 mcg/mL for serious MRSA infections.

The AUC Paradigm : Vancomycin antibacterial efficacy is driven by the 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio: AUC 24 / MIC = 400 to 600 mg ⋅ h/L \text{AUC}_{24}/\text{MIC} = 400\text{ to }600\text{ mg}\cdot\text{h/L} AUC 24 ​ / MIC = 400 to 600 mg ⋅ h/L

Safety Superiority : Targeting trough levels of 15 to 20 mcg/mL frequently produces supratherapeutic AUCs ( > 650 to 800 mg ⋅ h/L >650\text{ to }800\text{ mg}\cdot\text{h/L} > 650 to 800 mg ⋅ h/L ), increasing acute kidney injury rates three- to four-fold without enhancing microbiological clearance. AUC-guided dosing—derived using Bayesian modeling or two post-distribution concentrations (peak at 1–2h post-infusion and trough at 30 min pre-dose)—reduces nephrotoxicity while maintaining therapeutic cure rates.